Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival-Reference-Cited by-同舟云学术

Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival

Published:2017-04-10 Issue:8 Volume:52 Page:1126-1132
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Tandon N,Muchtar E,Sidana S,Dispenzieri A,Lacy M Q,Dingli D,Buadi F K,Hayman S R,Chakraborty R,Hogan W J,Gonsalves W,Warsame R,Kourelis T V,Leung N,Kapoor P,Kumar S K,Gertz M A

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt201768.pdf

Reference24 articles.

1. Comenzo RL, Vosburgh E, Simms RW, Bergethon P, Sarnacki D, Finn K et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 1996; 88: 2801–2806.

2. Majolino I, Marceno R, Pecoraro G, Scime R, Vasta S, Liberti G et al. High-dose therapy and autologous transplantation in amyloidosis-AL. Haematologica 1993; 78: 68–71.

3. Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 2011; 118: 4346–4352.

4. Cordes S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D et al. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Cancer 2012; 118: 6105–6109.

5. Dispenzieri A, Seenithamby K, Lacy MQ, Kumar SK, Buadi FK, Hayman SR et al. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. Bone Marrow Transplant 2013; 48: 1302–1307.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long‐term outcomes of renal AL amyloidosis patients undergoing autologous stem cell transplantation: Validating the performance of the renal staging system;American Journal of Hematology;2024-08-29

2. Treatment of AL amyloidosis in the era of novel immune and cellular therapies;Frontiers in Oncology;2024-06-28

3. Autologous hematopoietic stem cell transplantation conditioning regimens and chimeric antigen receptor T cell therapy in various diseases;World Journal of Transplantation;2024-03-18

4. Risk factors, treatments and outcomes of patients with light chain amyloidosis who relapse after autologous stem cell transplantation;Bone Marrow Transplantation;2023-12-26

5. Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL Amyloidosis;Cells;2023-12-18